Effect of bupropion on cognitive function in schizophrenia: A double-blind placebo and controlled study
Not Applicable
Completed
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT201509055280N20
- Lead Sponsor
- Vice chancellor for research of Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Inclusion criteria were a DSM-IV-TR diagnosis of schizophrenia, smoking at least 10 cigarettes a day.exclusion criteria were major depressive, manic, or hypomanic episode, and seizure disorder. And having contraindications for use of bupropion.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Psychotic and anti-psychotic symptoms assessment. Timepoint: beginning of study, 14th and 28th day of study. Method of measurement: Brief psychiatric rating scale (BPRS).;Positive and Negative Symptoms Scale. Timepoint: beginning of study, 14th and 28th day of study. Method of measurement: Positive and Negative Symptoms Scale (PANSS).;Memory. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: ( WMS ) Wechsler Memory Scale.;Executive functions. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: (WCST) Wisconsin Card Sorting Test.;Selective attention and cognitive flexibility. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: Stroop test.;Memory. Timepoint: in begging of study, 2nd, 7th, 14th, 28th of study. Method of measurement: Digit Span.
- Secondary Outcome Measures
Name Time Method